BioCentury | Sep 6, 2019
Emerging Company Profile

Cullgen: boosting the breadth of E3 ligases for protein degradation

...Undisclosed Number of employees: 40 Funds raised: $31 million Investors: Sequoia Capital China, HighLight Capital, GNI...
BioCentury | Apr 26, 2019
Financial News

Continent files for IPO in Hong Kong

...Ltd. (Tokyo:2160). GNI and its units own about 56% of Continent's shares. Elizabeth S. Eaton, Staff Writer GNI...
BioCentury | Mar 2, 2018
Financial News

Cullgen raises $15M seed round

...San Diego, Calif.) said it raised $15 million on March 1 in seed funding from GNI...
...technology that will initially focus on cancer and potentially expand into inflammatory and autoimmune diseases. GNI...
BioCentury | Mar 1, 2018
Financial News

Cullgen raises $15M seed round

...Cullgen Inc. said Thursday it raised $15 million in seed funding from GNI Group Ltd. The...
...technology that will initially focus on cancer and potentially expand into inflammatory and autoimmune diseases. GNI...
BioCentury | Apr 18, 2017
Distillery Therapeutics

Neurology

...could include identifying and testing additional compounds that promote MSR-1 expression. TMRC Co. Ltd. , GNI...
BioCentury | Apr 7, 2017
Finance

Fade to black

...$7 billion of equity value. The standout performer was Japanese fibrosis and liver disease company GNI...
...Exact Sciences Corp. (NASDAQ:EXAS), Madison, Wis. Global Blood Therapeutics Inc. (NASDAQ:GBT), South San Francisco, Calif. GNI...
...& Analytics CB-1158 CER-001 Cologuard Etuary NKTR-181 tezacaftor (VX-661)/ivacaftor volanesorsen AMAG Pharmaceuticals Inc. Argos Therapeutics Inc. Calithera Biosciences Inc. Cerenis Therapeutics S.A. Exact Sciences Corp. Global Blood Therapeutics Inc. GNI...
BioCentury | Jun 5, 2014
Distillery Therapeutics

Indication: Cancer

...steps include evaluating an anti-TGFB therapeutic in a Phase I trial. InterMune Inc., Cipla Ltd., GNI...
BioCentury | Jun 5, 2014
Distillery Therapeutics

Indication: Musculoskeletal disease

...steps include evaluating an anti-TGFB therapeutic in a Phase I trial. InterMune Inc., Cipla Ltd., GNI...
BioCentury | Feb 28, 2013
Politics & Policy

Indian committee proposes adjusted reference prices

...GNI) with purchasing power parity. According to the World Bank, in 2009 India's per capita GNI...
...or 9% of the $39,660 in Canada, the reference country with the highest per capita GNI...
BioCentury | Apr 23, 2012
Clinical News

EpiCept, GNI preclinical data

...Bulletin. EpiCept did not disclose next steps for the small molecule inhibitor of caspases . GNI...
...Australia and New Zealand (see BioCentury, July 21, 2008). EpiCept Corp. (OTCQX:EPCT; SSE:EPCT), Tarrytown, N.Y. GNI...
Items per page:
1 - 10 of 24
BioCentury | Sep 6, 2019
Emerging Company Profile

Cullgen: boosting the breadth of E3 ligases for protein degradation

...Undisclosed Number of employees: 40 Funds raised: $31 million Investors: Sequoia Capital China, HighLight Capital, GNI...
BioCentury | Apr 26, 2019
Financial News

Continent files for IPO in Hong Kong

...Ltd. (Tokyo:2160). GNI and its units own about 56% of Continent's shares. Elizabeth S. Eaton, Staff Writer GNI...
BioCentury | Mar 2, 2018
Financial News

Cullgen raises $15M seed round

...San Diego, Calif.) said it raised $15 million on March 1 in seed funding from GNI...
...technology that will initially focus on cancer and potentially expand into inflammatory and autoimmune diseases. GNI...
BioCentury | Mar 1, 2018
Financial News

Cullgen raises $15M seed round

...Cullgen Inc. said Thursday it raised $15 million in seed funding from GNI Group Ltd. The...
...technology that will initially focus on cancer and potentially expand into inflammatory and autoimmune diseases. GNI...
BioCentury | Apr 18, 2017
Distillery Therapeutics

Neurology

...could include identifying and testing additional compounds that promote MSR-1 expression. TMRC Co. Ltd. , GNI...
BioCentury | Apr 7, 2017
Finance

Fade to black

...$7 billion of equity value. The standout performer was Japanese fibrosis and liver disease company GNI...
...Exact Sciences Corp. (NASDAQ:EXAS), Madison, Wis. Global Blood Therapeutics Inc. (NASDAQ:GBT), South San Francisco, Calif. GNI...
...& Analytics CB-1158 CER-001 Cologuard Etuary NKTR-181 tezacaftor (VX-661)/ivacaftor volanesorsen AMAG Pharmaceuticals Inc. Argos Therapeutics Inc. Calithera Biosciences Inc. Cerenis Therapeutics S.A. Exact Sciences Corp. Global Blood Therapeutics Inc. GNI...
BioCentury | Jun 5, 2014
Distillery Therapeutics

Indication: Cancer

...steps include evaluating an anti-TGFB therapeutic in a Phase I trial. InterMune Inc., Cipla Ltd., GNI...
BioCentury | Jun 5, 2014
Distillery Therapeutics

Indication: Musculoskeletal disease

...steps include evaluating an anti-TGFB therapeutic in a Phase I trial. InterMune Inc., Cipla Ltd., GNI...
BioCentury | Feb 28, 2013
Politics & Policy

Indian committee proposes adjusted reference prices

...GNI) with purchasing power parity. According to the World Bank, in 2009 India's per capita GNI...
...or 9% of the $39,660 in Canada, the reference country with the highest per capita GNI...
BioCentury | Apr 23, 2012
Clinical News

EpiCept, GNI preclinical data

...Bulletin. EpiCept did not disclose next steps for the small molecule inhibitor of caspases . GNI...
...Australia and New Zealand (see BioCentury, July 21, 2008). EpiCept Corp. (OTCQX:EPCT; SSE:EPCT), Tarrytown, N.Y. GNI...
Items per page:
1 - 10 of 24